Literature DB >> 16953272

Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells.

Katharina Pfistershammer1, Johannes Stöckl, Jürgen Siekmann, Peter L Turecek, Hans Peter Schwarz, Birgit M Reipert.   

Abstract

Several lines of evidence have shown that antibody responses to coagulation factor VIII (FVIII) in patients with hemophilia A depend on the help of activated CD4(+) T cells. The primary activation of CD4(+) T cells requires interaction with mature dendritic cells (DCs) that present antigenic peptides in the context of MHC class II and express costimulatory molecules. Maturation of DCs requires danger signals provided by exogenous or endogenous stimuli such as pathogen-derived products or inflammatory cytokines. We asked the question whether FVIII itself, FVIII complexed with von Willebrand factor (VWF) or thrombin-activated FVIII contain danger signals for human DCs that induce the upregulation of costimulatory molecules or the expression of proinflammatory cytokines necessary for effective activation of CD4(+) T cells. Human peripheral monocytes were differentiated into DCs. FVIII, thrombin-activated FVIII, VWF, VWF-FVIII, lipopolysaccharide (LPS), LPS + FVIII, LPS + VWF or LPS + FVIII-VWF were added either on day 0 or on day 5 of differentiation cultures. Differentiation markers, cytokines in cell culture supernatants and the capacity of DCs to stimulate autologous and allogeneic T cells were analysed after seven days of differentiation cultures. Our results indicate that neither FVIII, thrombin-activated FVIII, VWF nor a complex of FVIII and VWF modulate the maturation of human DCs or their capacity to stimulate autologous or allogeneic T cells. We conclude that neither of these proteins present danger signals to human DCs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16953272     DOI: 10.1160/TH05-11-0729

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  11 in total

1.  Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

Review 2.  Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Authors:  Johannes Oldenburg; Sébastien Lacroix-Desmazes; David Lillicrap
Journal:  Haematologica       Date:  2015-02       Impact factor: 9.941

3.  The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.

Authors:  Bagirath Gangadharan; Mathieu Ing; Sandrine Delignat; Ivan Peyron; Maud Teyssandier; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

4.  A role for thrombin in the initiation of the immune response to therapeutic factor VIII.

Authors:  Jonathan Skupsky; Ai-Hong Zhang; Yan Su; David W Scott
Journal:  Blood       Date:  2009-09-30       Impact factor: 22.113

Review 5.  Factor VIII inhibitors: risk factors and methods for prevention and immune modulation.

Authors:  Ai Hong Zhang; Jonathan Skupsky; David W Scott
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

6.  Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice.

Authors:  Qizhen Shi; Christopher V Carman; Yingyu Chen; Peter T Sage; Feng Xue; Xin M Liang; Gary E Gilbert
Journal:  Blood Adv       Date:  2020-05-26

7.  Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators.

Authors:  Ahmad Faisal Karim; Anthony R Soltis; Gauthaman Sukumar; Christoph Königs; Nadia P Ewing; Clifton L Dalgard; Matthew D Wilkerson; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

Review 8.  Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?

Authors:  Aditi Varthaman; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2018-12-04       Impact factor: 9.941

Review 9.  Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1.

Authors:  Davide Matino; Sajjad Afraz; George Zhao; Paul Tieu; Marco Gargaro; Francesca Fallarino; Alfonso Iorio
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561

Review 10.  To clear or to fear: An innate perspective on factor VIII immunity.

Authors:  Jesse Derek Lai; Maria Teofana Georgescu; Christine Hough; David Lillicrap
Journal:  Cell Immunol       Date:  2015-10-28       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.